Please ensure Javascript is enabled for purposes of website accessibility

A Sell-the-News Buying Opportunity

By Brian Orelli, PhD - Updated Apr 6, 2017 at 5:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Ariad gets knocked down despite presenting good data.

The likelihood of a sell-the-news event after a biotech releases new data seems to be directly linked to the run-up a biotech has experienced going into the release. So it shouldn't come as much of a shock that Ariad Pharmaceuticals (Nasdaq: ARIA) sold off 8.2% yesterday following the release of the abstract for its leukemia treatment ponatinib to be presented at the American Society of Hematology annual meeting next month. The biotech was up 135% this year going into yesterday.

Because, frankly, the data looks pretty good.

Ariad is going after patients that have failed Otsuka's and Bristol-Myers Squibb's (NYSE: BMY) Sprycel or Novartis' (NYSE: NVS) Tasigna, or have a mutation that doesn't allow them to be treated with those drugs. Of the chronic phase patients who had been assessed three months after starting ponatinib, 42% of patients resistant or intolerant to Sprycel or Tasigna responded to the drug. Patients with the mutation fared even better, with 57% responding.

The phase 2 trial was a single-arm, open-label trial, which means that all the patients got ponatinib and doctors and their patients knew they got the drug. While double-blinded trials comparing a drug candidate with standard therapy or placebo is the best way to tell if a drug works, it's hard to imagine that around half of the patients would start to improve on their own. These are sick patients with few options, after all.

In fact, this phase 2 trial should be enough to gain Food and Drug Administration approval given the unmet need. Seattle Genetics' (Nasdaq: SGEN) Adcetris was approved with just phase 2 data for the same reason.

If the full readout of the trial, which is expected in the first half of next year, produces the same solid results at six months, Ariad shouldn't have any problems getting the drug approved.

Keep track of Ariad as it further develops ponatinib by adding it to the Fool's free My Watchlist service. Just click here to get started.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Novartis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novartis AG Stock Quote
Novartis AG
NVS
$85.68 (0.12%) $0.10
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$75.57 (1.49%) $1.11
Seagen Inc. Stock Quote
Seagen Inc.
SGEN
$170.14 (-2.24%) $-3.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.